Shownotes
Only one in three eligible lung cancer patients receives the targeted therapy they should get. That is not a failure of science. It is a failure of delivery. After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data. Yet too many breakthroughs still fail to reach the bedside. Patients fall through fragmented systems. Data does ...

